Neurosense Partners With Phasev To Optimize Upcoming Als Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Therapeutics and PhaseV have partnered to use causal machine learning to analyze and optimize the planned Phase 3 trial of PrimeC as a treatment for ALS. The results show a high probability of success in multiple subgroups, providing important insights for study design and patient enrollment. This collaboration aims to develop a more effective treatment for ALS.